Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Murray, UT
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Cleveland, OH
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
East Norriton, PA
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
East Norriton, PA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Fresno, CA
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Dayton, OH
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Jonesboro, AR
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Saint George, UT
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Saint George, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
East Syracuse, NY
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Dalton, GA
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Dalton, GA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Louisville, KY
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Palmdale, CA
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Palmdale, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Rydal, PA
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Rydal, PA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Kettering, OH
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated:  11/7/2014
Clinical Research Facility
mi
from
Louisville, KY
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
Status: Enrolling
Updated: 11/7/2014
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Metabolic Abnormalities in HIV-infected Persons
Metabolic Abnormalities in HIV-infected Persons
Status: Enrolling
Updated:  11/13/2014
Tufts Medical Center
mi
from
Boston, MA
Metabolic Abnormalities in HIV-infected Persons
Metabolic Abnormalities in HIV-infected Persons
Status: Enrolling
Updated: 11/13/2014
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics
Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics
Status: Enrolling
Updated:  11/21/2014
Spectrum Health Hospitals
mi
from
Grand Rapids, MI
Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics
Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics
Status: Enrolling
Updated: 11/21/2014
Spectrum Health Hospitals
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Herpes Simplex Type 1 Suppression in Hepatitis C
HSV-1 Suppression in HCV Infected Veterans Who Are Seronegative for HSV-2
Status: Enrolling
Updated:  11/24/2014
G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS
mi
from
Jackson, MS
Herpes Simplex Type 1 Suppression in Hepatitis C
HSV-1 Suppression in HCV Infected Veterans Who Are Seronegative for HSV-2
Status: Enrolling
Updated: 11/24/2014
G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS
mi
from
Jackson, MS
Click here to add this to my saved trials
Serosorting Intervention for HIV Negative MSM
Serosorting Intervention for HIV Negative MSM
Status: Enrolling
Updated:  12/1/2014
SHARE Project
mi
from
Atlanta, GA
Serosorting Intervention for HIV Negative MSM
Serosorting Intervention for HIV Negative MSM
Status: Enrolling
Updated: 12/1/2014
SHARE Project
mi
from
Atlanta, GA
Click here to add this to my saved trials
MRSA in a Trauma Population: Does Decolonization Prevent Infection?
Methicillin-resistant Staphylococcus Aureus in a Trauma Population: Does Decolonization Prevent Infection?
Status: Enrolling
Updated:  12/16/2014
Erlanger Hospital
mi
from
Chattanooga, TN
MRSA in a Trauma Population: Does Decolonization Prevent Infection?
Methicillin-resistant Staphylococcus Aureus in a Trauma Population: Does Decolonization Prevent Infection?
Status: Enrolling
Updated: 12/16/2014
Erlanger Hospital
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.
Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123 Administered Orally to Healthy Adults
Status: Enrolling
Updated:  12/18/2014
Quintiles Phase I Services - Overland Park
mi
from
Overland Park, KA
Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.
Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123 Administered Orally to Healthy Adults
Status: Enrolling
Updated: 12/18/2014
Quintiles Phase I Services - Overland Park
mi
from
Overland Park, KA
Click here to add this to my saved trials
Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection
Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  12/26/2014
University of California, Irvine Medical Center
mi
from
Orange, CA
Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection
Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 12/26/2014
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers
Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers
Status: Enrolling
Updated:  1/7/2015
center for envionmental medicine asthma an lung biology at the EPA
mi
from
Chapel Hill, NC
Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers
Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers
Status: Enrolling
Updated: 1/7/2015
center for envionmental medicine asthma an lung biology at the EPA
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
University of Arkansas Medical Center
mi
from
Little Rock, AR
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
University of Arkansas Medical Center
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
University of California at San Diego
mi
from
San Diego, CA
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
University of California at San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
Connecicut Children's Hospital
mi
from
Hartford, CT
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
Connecicut Children's Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
University of Louisville
mi
from
Louisville, KY
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
Columbia University
mi
from
New York, NY
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
Duke Medical Center
mi
from
Durham, NC
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
Duke Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
Pediatric Pharmacology
mi
from
Toledo, OH
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
Pediatric Pharmacology
mi
from
Toledo, OH
Click here to add this to my saved trials
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated:  1/23/2015
Texas Children's Hospital - Clinical Care Center
mi
from
Houston, TX
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
Status: Enrolling
Updated: 1/23/2015
Texas Children's Hospital - Clinical Care Center
mi
from
Houston, TX
Click here to add this to my saved trials
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated:  1/29/2015
Central California Ear, Nose, and Throat
mi
from
Fresno, CA
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated: 1/29/2015
Central California Ear, Nose, and Throat
mi
from
Fresno, CA
Click here to add this to my saved trials
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated:  1/29/2015
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated: 1/29/2015
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated:  1/29/2015
Charlotte Eye Ear Nose and Throat Associates
mi
from
Matthews, NC
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated: 1/29/2015
Charlotte Eye Ear Nose and Throat Associates
mi
from
Matthews, NC
Click here to add this to my saved trials
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated:  1/29/2015
Piedmont Ear, Nose and Throat
mi
from
Winston-Salem, NC
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated: 1/29/2015
Piedmont Ear, Nose and Throat
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated:  1/29/2015
Carolina Ear, Nose and Throat
mi
from
Orangeburg, SC
Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement
Status: Enrolling
Updated: 1/29/2015
Carolina Ear, Nose and Throat
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Birmingham, AL
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Little Rock, AR
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Little Rock, AR
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Colton, CA
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Colton, CA
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Escondido, CA
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Escondido, CA
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Long Beach, CA
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Modesto, CA
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Modesto, CA
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
San Diego, CA
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated:  2/3/2015
Clinical Research Facility
mi
from
Lafayette, CO
Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
Status: Enrolling
Updated: 2/3/2015
Clinical Research Facility
mi
from
Lafayette, CO
Click here to add this to my saved trials